ImmunityBio Shares Surge on European Regulatory Milestone
Published on 02/23/2026 at 12:40 | Redaktion boerse-global.de
The biotechnology sector has a standout performer following a critical regulatory decision. ImmunityBio's equity experienced a dramatic upward move after European regulators approved its cancer therapy, ANKTIVA. The central question now is whether the commercial launch can justify the soaring market expectations that have followed this news.
On Tuesday, February 18, the European Commission granted conditional marketing authorization for ANKTIVA. The approval covers its use in combination with Bacillus Calmette-Guérin (BCG) for treating specific forms of bladder cancer in adults. This decision expands the drug's approved territory to a total of 33 countries, building on prior authorizations from regulators in the United States, the United Kingdom, and Saudi Arabia.
Clinical trial data supporting the application demonstrated a complete response rate of 71 percent among treated patients.
Market Reaction and Trading Dynamics
Investor sentiment turned overwhelmingly positive following the announcement. On the day of the news, the company's stock price leaped by more than 40 percent to reach $8.54. The trading activity was particularly notable, with volume hitting 78.5 million shares—a figure that exceeded the three-month average by nearly 180 percent.
Unlike many short-lived rallies in the biotech space, ImmunityBio managed to consolidate these gains. The share price stabilized over the subsequent trading sessions, closing the week at $8.70 on Friday. This valuation places the company's current market capitalization at approximately $8.6 billion.
Operational Execution and Financial Momentum
The company's leadership is moving swiftly to capitalize on this regulatory success. A distribution partnership with Accord Healthcare was finalized just one day after the EU approval. The strategy involves deploying over 100 sales and medical specialists across Europe to spearhead the commercial launch in the UK and EU markets. A newly established Irish subsidiary will provide logistical support for this expansion.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Concurrently, the firm is broadening its commercial footprint in the Middle East. In collaboration with Biopharma and Cigalah Healthcare, distribution has commenced in Saudi Arabia, where an accelerated approval was secured in January.
This operational push aligns with already accelerating revenue growth. For the 2025 fiscal year, ImmunityBio reported preliminary product revenue of $113 million, representing a staggering 700 percent increase compared to the previous year.
All eyes are now on March 2, when the company is expected to release detailed fourth-quarter 2025 results. Beyond the headline sales figures, key points of focus will be the efficiency of managing costs associated with this aggressive global rollout and the progress toward pipeline targets set for late 2026.
Ad
ImmunityBio Stock: New Analysis - 23 February
Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
